Free Trial
NASDAQ:AARD

Aardvark Therapeutics (AARD) Stock Price, News & Analysis

Aardvark Therapeutics logo
$10.52 +0.22 (+2.14%)
As of 05/30/2025 04:00 PM Eastern

About Aardvark Therapeutics Stock (NASDAQ:AARD)

Key Stats

Today's Range
$10.38
$10.67
50-Day Range
$7.00
$12.86
52-Week Range
$4.88
$19.58
Volume
18,454 shs
Average Volume
106,908 shs
Market Capitalization
$228.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.25
Consensus Rating
Buy

Company Overview

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Receive AARD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aardvark Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AARD Stock News Headlines

Banks aren’t ready for this altcoin—are you?
I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. This is about being in the right place at the right time – and I believe that time is now.
See More Headlines

AARD Stock Analysis - Frequently Asked Questions

Aardvark Therapeutics' stock was trading at $13.30 at the beginning of 2025. Since then, AARD shares have decreased by 20.9% and is now trading at $10.52.
View the best growth stocks for 2025 here
.

Aardvark Therapeutics, Inc. (NASDAQ:AARD) posted its earnings results on Wednesday, May, 14th. The company reported ($0.71) earnings per share for the quarter, missing analysts' consensus estimates of ($0.70) by $0.01.

Aardvark Therapeutics (AARD) raised $100 million in an IPO on Friday, February 14th 2025. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cantor and RBC Capital Markets served as the underwriters for the IPO.

Aardvark Therapeutics' top institutional shareholders include Decheng Capital LLC (18.06%), Cormorant Asset Management LP (3.69%), Braidwell LP (2.30%) and Adage Capital Partners GP L.L.C. (1.15%). Insiders that own company stock include Tien-Li Lee and Nelson Sun.
View institutional ownership trends
.

Shares of AARD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/14/2025
Today
6/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AARD
Previous Symbol
NASDAQ:AARD
Web
N/A
Fax
N/A
Employees
18
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$31.25
High Stock Price Target
$50.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+197.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$228.24 million
Optionable
N/A
Beta
N/A
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

This page (NASDAQ:AARD) was last updated on 6/1/2025 by MarketBeat.com Staff
From Our Partners